U.S. market Closed. Opens in 1 day 19 hours 52 minutes

ADXN | Addex Therapeutics Ltd Stock Fundamentals

(Stock Exchange: NASDAQ)
Analyzing fundamentals for ADXN we got that it has weak fundamentals where Valuation is considered to be slightly overvalued, Profitability is stunning wealthy, Growth is desperately bad and Health is frighteningly weak.

Valuation (50%)

Company Industry
P/E Ratio (TTM) 1.04 -19.34
PEG Ratio (TTM) 0.02 -6.10
P/S Ratio (TTM) 17.94 45.38
P/B Ratio (TTM) 0.51 29.05
P/FCF Ratio (TTM) -1.77 -3.91
Price to 5YR AVG Earnings Ratio -16.59 -6.78
Price to 5YR AVG FCF Ratio -0.81 -12.87

Profitability (100%)

Company Industry
ROA (TTM) 44.42% -15.27%
ROE (TTM) 92.06% 26.93%
Net Profit Margin (TTM) 919.40% -648.73%
ROIC 5YR AVG 455.84% -8.24%

Growth (17%)

4QTR AVG 3YR AVG 5YR AVG
EPS 103.98% -224.22% -121.06%
Revenue -26.08% -14.27% -16.13%
Net Income 97.02% -268.34% -158.25%
Cash Flow -29.96% -230.16% -130.18%

Health (28%)

Company Industry
Current Ratio (TTM) 4.59 5.58
Quick Ratio (TTM) 4.59 5.36
D/E Ratio (TTM) N/A 0.98
Interest Coverage (TTM) -479.22 -6.85
Piotroski F-Score 4 5
Altman Z-Score N/A 12.49
LTL to 5YR AVG FCF -0.01 0.08
Shares Outstanding Growth 5YR AVG 27.84% 37.38%
An error has occurred. This application may no longer respond until reloaded. Reload 🗙